Roivant Sciences Ltd. business relationships

Companies named in Roivant Sciences Ltd.’s 10-K filed 2026-05-20, and public companies whose annual reports name Roivant Sciences Ltd.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 6.6 / 10
AI naming: 100 / 100
Agent readiness: 5 / 100
AI adoption: 0 / 100

Named in Roivant Sciences Ltd.’s annual report 11

BayerLicensor7.7
“Pursuant to the Bayer-Pulmovant License Agreement, Bayer granted Pulmovant an exclusive, worldwide, sublicensable, royalty-bearing license under certain patents and know-how to use, develop, commercialize and manufacture mosliciguat compounds and products containing or comprising such compounds for...” SEC filing
PFIZER INC (PFE)Licensor7.7
“Pursuant to the Pfizer-Priovant License Agreement, Pfizer granted Priovant (i) an exclusive, worldwide, sublicensable, royalty-bearing license under certain patents and (ii) a non-exclusive, worldwide, sublicensable, royalty-bearing license under certain know-how, in each case, to develop, manufactu...” SEC filing
PFIZER INC (PFE)Partner7.7
“License and Collaboration Agreement with Pfizer, Inc.” SEC filing
Moderna, Inc. (MRNA)Licensor6.1
“Payments by Moderna under the Settlement Agreement will be made directly to Genevant and Arbutus consistent with the terms of a cross-license agreement (as amended, the "Cross-License Agreement") entered between Genevant (as assignee of GSL) and Arbutus.” SEC filing
Arbutus Biopharma Corp (ABUS)Licensor5.4
“Cross-License Agreement with Arbutus Biopharma Corporation” SEC filing
Immunovant, Inc. (IMVT)Licensor5.4
“• the fact that Immunovant relies on a license agreement with HanAll Biopharma Co., Ltd. to provide the rights to the core intellectual property relating to IMVT-1402 and batoclimab;” SEC filing
Immunovant, Inc. (IMVT)Payor5.4
“As we approach commercialization for our other product candidates, including IMVT-1402 at Immunovant and mosliciguat at Pulmovant, we anticipate they will similarly work to build out sales and marketing functions appropriate to their product candidates, the indications for which they are being devel...” SEC filing
Editas Medicine, Inc. (EDIT)Partner4.9
“• Some current collaboration partners include Editas Medicine, Epitopea, Mammoth Biotechnologies and Repair Biotechnologies.” SEC filing
Repair BiotechnologiesPartner4.7
“• Some current collaboration partners include Editas Medicine, Epitopea, Mammoth Biotechnologies and Repair Biotechnologies.” SEC filing
Genevant Sciences GmbHLicensor4.6
“First Amendment to Cross License Agreement, dated as of June 27, 2018, by and among Genevant Sciences Ltd., Genevant Sciences GmbH and Arbutus Biopharma Corporation” SEC filing
EpitopeaPartner3.5
“• Some current collaboration partners include Editas Medicine, Epitopea, Mammoth Biotechnologies and Repair Biotechnologies.” SEC filing

Companies whose annual reports name Roivant Sciences Ltd. 1

Immunovant, Inc. (IMVT)names it as licensor5.4
“Assignment and Assumption Agreement, dated as of December 7, 2018, by and between Immunovant Sciences GmbH and Roivant Sciences GmbH, relating to the License Agreement by and between Roivant Sciences GmbH and HanAll BioPharma Co., Ltd.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.